1. Home
  2. AFMD vs MYNA Comparison

AFMD vs MYNA Comparison

Compare AFMD & MYNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AFMD
  • MYNA
  • Stock Information
  • Founded
  • AFMD 2000
  • MYNA 2009
  • Country
  • AFMD Germany
  • MYNA Germany
  • Employees
  • AFMD N/A
  • MYNA N/A
  • Industry
  • AFMD Biotechnology: Pharmaceutical Preparations
  • MYNA
  • Sector
  • AFMD Health Care
  • MYNA
  • Exchange
  • AFMD Nasdaq
  • MYNA Nasdaq
  • Market Cap
  • AFMD 17.5M
  • MYNA 14.9M
  • IPO Year
  • AFMD 2014
  • MYNA 2021
  • Fundamental
  • Price
  • AFMD $1.15
  • MYNA $0.44
  • Analyst Decision
  • AFMD Strong Buy
  • MYNA
  • Analyst Count
  • AFMD 5
  • MYNA 0
  • Target Price
  • AFMD $13.50
  • MYNA N/A
  • AVG Volume (30 Days)
  • AFMD 363.4K
  • MYNA 2.0M
  • Earning Date
  • AFMD 11-14-2024
  • MYNA 01-28-2025
  • Dividend Yield
  • AFMD N/A
  • MYNA N/A
  • EPS Growth
  • AFMD N/A
  • MYNA N/A
  • EPS
  • AFMD N/A
  • MYNA N/A
  • Revenue
  • AFMD $6,287,085.00
  • MYNA $5,957,776.00
  • Revenue This Year
  • AFMD N/A
  • MYNA $203.73
  • Revenue Next Year
  • AFMD $212.48
  • MYNA $203.84
  • P/E Ratio
  • AFMD N/A
  • MYNA N/A
  • Revenue Growth
  • AFMD N/A
  • MYNA 21.89
  • 52 Week Low
  • AFMD $1.03
  • MYNA $0.33
  • 52 Week High
  • AFMD $8.95
  • MYNA $5.89
  • Technical
  • Relative Strength Index (RSI)
  • AFMD 28.57
  • MYNA 37.96
  • Support Level
  • AFMD $1.03
  • MYNA $0.49
  • Resistance Level
  • AFMD $1.41
  • MYNA $0.97
  • Average True Range (ATR)
  • AFMD 0.11
  • MYNA 0.15
  • MACD
  • AFMD 0.05
  • MYNA -0.01
  • Stochastic Oscillator
  • AFMD 23.53
  • MYNA 4.32

About AFMD Affimed N.V.

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.

About MYNA Mynaric AG American Depository Shares

Mynaric AG operates in the communication equipment business sector. The company is engaged in the manufacture and sale of products and projects and the provision of services in the field of laser technology, in particular in the aerospace, telematics, and satellite services sectors. It operates in two segments: Air and Space. The space segment comprises CONDOR terminals, and the Air segment comprises HAWK terminals. The company's product portfolio consists of Optical ground stations, Air-to-ground terminals, Air-to-air terminals, Space terminals, and Custom products and subcomponents. Its applications consist of high-altitude networks, remote eyes, satellite constellations, earth observation satellites, and others. Geographically, its key revenue is derived from the United States.

Share on Social Networks: